An updated review on oral protein-based antigen vaccines efficiency and delivery approaches: a special attention to infectious diseases

Hashemi, Parisa; Mahmoodi, Shirin; Ghasemian, Abdolmajid

doi:10.1007/s00203-023-03629-2

Cited by 5 publications

(1 citation statement)

References 225 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the peptide-coupled polymeric nature of the present vaccine prototype, a good mucosal response could be expected. However, if oral immune responses needed to be enhanced, nanoparticles [ 96 ], mucosal adjuvants such as E coli double mutant thermolabile toxin (dmLT) [ 97 , 98 ], multiple mutated choleratoxin (mmCT) [ 99 ] α-galactosylceramide (α-GalCer) [ 100 ], chitosan [ 101 ], among others could be used [ 102 – 104 ]. The administration of oral vaccines involves the use of substantial amounts of antigen to counteract its degradation in the gastrointestinal tract [ 103 ].…”

Section: Discussionmentioning

confidence: 99%

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19

Valdez‑Cruz,

Rosiles-Becerril,

Martínez-Olivares

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

Background Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently presented for generating neutralizing antibodies and as a model for new vaccines. Results This work presents the development of an applicable technology through the oral administration of the SARS-CoV-2 RBD antigen fused with a peptide to improve its antigenic presentation. We focused on the development and production of the recombinant receptor binding domain (RBD) produced in E. coli modified with the addition of amino acids extension designed to improve antigen presentation. The production was carried out in shake flask and bioreactor cultures, obtaining around 200 mg/L of the antigen. The peptide-fused RBD and peptide-free RBD proteins were characterized and compared using SDS-PAGE gel, high-performance chromatography, and circular dichroism. The peptide-fused RBD was formulated in an oil-in-water emulsion for oral mice immunization. The peptide-fused RBD, compared to RBD, induced robust IgG production in mice, capable of recognizing the recombinant RBD in Enzyme-linked immunosorbent assays. In addition, the peptide-fused RBD generated neutralizing antibodies in the sera of the dosed mice. The formulation showed no reactive episodes and no changes in temperature or vomiting. Conclusions Our study demonstrated the effectiveness of the designed peptide added to the RBD to improve antigen immunostimulation by oral administration. Graphical Abstract

show abstract